title: CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine.
abstract: Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncoprotein which participates in inhibiting tumor apoptosis in pancreatic cancer cells. Using immunohistochemical staining, we investigated the expression of CIP2A protein in 72 cases of human pancreatic ductal adenocarcinoma (PDAC) tissue and 27 cases of adjacent normal pancreatic tissue. The positive rate of CIP2A protein expression in pancreatic cancer tissue was70.83 %, which was significantly higher than that in adjacent non- cancerous pancreatic tissue (11.11%). The expression of CIP2A was found to be correlated with TNM stage, but not correlated with age, gender, tumor location, smoking status, alcohol consumption, diabetes, high blood pressure, BMI, tumor size, lymph node metastasis or distant metastases. Kaplan- Meier survival analysis showed that patients with positive CIP2A protein expression had a lower overall survival rate than patients without CIP2A expression. COX regression analysis indicated that expression of CIP2A was an independent prognostic factor for pancreatic ductal adenocarcinoma. In addition, down-regulation of CIP2A inhibited cell proliferation and increased sensitivity to gemcitabine in pancreatic cancer cells by decreasing AKT signaling pathway. Our results indicated that down-regulation of CIP2A could be a novel therapeutic strategy for pancreatic cancer.
authors.affiliation: Department of Hepatobiliary and Pancreatic Surgery, Northern Jiangsu People's Hospital, Clinical Medical College of Yangzhou University, Yangzhou City, Jiangsu Province of P. R. China, 225001.
authors.forename: Peng
authors.initials: P
authors.lastname: Xu
authors.affiliation: Department of Hepatobiliary and Pancreatic Surgery, Northern Jiangsu People's Hospital, Clinical Medical College of Yangzhou University, Yangzhou City, Jiangsu Province of P. R. China, 225001.
authors.forename: Jie
authors.initials: J
authors.lastname: Yao
authors.affiliation: Department of Hepatobiliary and Pancreatic Surgery, Northern Jiangsu People's Hospital, Clinical Medical College of Yangzhou University, Yangzhou City, Jiangsu Province of P. R. China, 225001.
authors.forename: Jin
authors.initials: J
authors.lastname: He
authors.affiliation: Department of Hepatobiliary and Pancreatic Surgery, Northern Jiangsu People's Hospital, Clinical Medical College of Yangzhou University, Yangzhou City, Jiangsu Province of P. R. China, 225001.
authors.forename: Long
authors.initials: L
authors.lastname: Zhao
authors.affiliation: Department of Hepatobiliary and Pancreatic Surgery, Northern Jiangsu People's Hospital, Clinical Medical College of Yangzhou University, Yangzhou City, Jiangsu Province of P. R. China, 225001.
authors.forename: Xiaodong
authors.initials: X
authors.lastname: Wang
authors.affiliation: Department of Hepatobiliary and Pancreatic Surgery, Northern Jiangsu People's Hospital, Clinical Medical College of Yangzhou University, Yangzhou City, Jiangsu Province of P. R. China, 225001.
authors.forename: Zhennan
authors.initials: Z
authors.lastname: Li
authors.affiliation: Department of Hepatobiliary and Pancreatic Surgery, Northern Jiangsu People's Hospital, Clinical Medical College of Yangzhou University, Yangzhou City, Jiangsu Province of P. R. China, 225001.
authors.forename: Jianjun
authors.initials: J
authors.lastname: Qian
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D001324:Autoantigens / Q000235:genetics / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism; D021441:Carcinoma, Pancreatic Ductal / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary; D016022:Case-Control Studies; D049109:Cell Proliferation / Q000187:drug effects; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins; D008207:Lymphatic Metastasis; D008297:Male; D008565:Membrane Proteins / Q000235:genetics / Q000378:metabolism*; D008875:Middle Aged; D009367:Neoplasm Staging; D010179:Pancreas / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D011379:Prognosis; D015996:Survival Rate; D014407:Tumor Cells, Cultured; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D001324:Autoantigens; D014408:Biomarkers, Tumor; C500266:CIP2A protein, human; D047908:Intracellular Signaling Peptides and Proteins; D008565:Membrane Proteins; D003841:Deoxycytidine; D000093542:Gemcitabine
keywords: CIP2A; gemcitabine; overall survival; pancreatic ductal adenocarcinoma; prognosis